User login
Highlights in Chronic Lymphocytic Leukemia From ASH 2020
Key studies were presented at the 2020 American Society of Hematology (ASH) meeting on next-generation BTK inhibitors, combination treatments, and CAR-T therapies for chronic lymphocytic leukemia (CLL).
Dr William Wierda of the MD Anderson Cancer Center in Houston, Texas, reviews updated data from the MURANO and CLL14 trials, both of which demonstrated durable and long-term remissions with targeted combination therapies.
Dr Wierda also reviews an analysis of the primary endpoint for the CAPTIVATE study, which examined ibrutinib plus venetoclax, and updated data for LOXO-305, a reversible inhibitor of BTK demonstrating clear activity and good tolerability.
He discusses two reports on the TRANSCEND anti-CD19 CAR T-cell trial. The first report compares CAR-T monotherapy to a combination of CAR-T therapy and ibrutinib. The second evaluates data from CAR-T monotherapy demonstrating a complete remission rate of 40%-60% along with undetectable MRD in bone marrow.
Finally, Dr Wierda reviews data from the UNITY phase 3 trial evaluating the combination of umbralisib plus ublituximab vs obinutuzumab plus chlorambucil in both the frontline and relapsed settings. The combination targeted therapy resulted in improved survival compared with the chemoimmunotherapy.
--
William G. Wierda, MD, PhD, Professor; Medical Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
William G. Wierda, MD, PhD, has disclosed the following relevant financial relationships:
Contracted research for: GlaxoSmithKline/Novartis; AbbVie; Genentech; Pharmacyclics LLC; Acerta Pharma, Inc.; Gilead Sciences; Juno Therapeutics; KITE Pharma; Sunesis; Miragen; Oncternal Therapeutics, Inc.; Cyclacel; Loxo Oncology, Inc.; Janssen; Xencor.
Key studies were presented at the 2020 American Society of Hematology (ASH) meeting on next-generation BTK inhibitors, combination treatments, and CAR-T therapies for chronic lymphocytic leukemia (CLL).
Dr William Wierda of the MD Anderson Cancer Center in Houston, Texas, reviews updated data from the MURANO and CLL14 trials, both of which demonstrated durable and long-term remissions with targeted combination therapies.
Dr Wierda also reviews an analysis of the primary endpoint for the CAPTIVATE study, which examined ibrutinib plus venetoclax, and updated data for LOXO-305, a reversible inhibitor of BTK demonstrating clear activity and good tolerability.
He discusses two reports on the TRANSCEND anti-CD19 CAR T-cell trial. The first report compares CAR-T monotherapy to a combination of CAR-T therapy and ibrutinib. The second evaluates data from CAR-T monotherapy demonstrating a complete remission rate of 40%-60% along with undetectable MRD in bone marrow.
Finally, Dr Wierda reviews data from the UNITY phase 3 trial evaluating the combination of umbralisib plus ublituximab vs obinutuzumab plus chlorambucil in both the frontline and relapsed settings. The combination targeted therapy resulted in improved survival compared with the chemoimmunotherapy.
--
William G. Wierda, MD, PhD, Professor; Medical Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
William G. Wierda, MD, PhD, has disclosed the following relevant financial relationships:
Contracted research for: GlaxoSmithKline/Novartis; AbbVie; Genentech; Pharmacyclics LLC; Acerta Pharma, Inc.; Gilead Sciences; Juno Therapeutics; KITE Pharma; Sunesis; Miragen; Oncternal Therapeutics, Inc.; Cyclacel; Loxo Oncology, Inc.; Janssen; Xencor.
Key studies were presented at the 2020 American Society of Hematology (ASH) meeting on next-generation BTK inhibitors, combination treatments, and CAR-T therapies for chronic lymphocytic leukemia (CLL).
Dr William Wierda of the MD Anderson Cancer Center in Houston, Texas, reviews updated data from the MURANO and CLL14 trials, both of which demonstrated durable and long-term remissions with targeted combination therapies.
Dr Wierda also reviews an analysis of the primary endpoint for the CAPTIVATE study, which examined ibrutinib plus venetoclax, and updated data for LOXO-305, a reversible inhibitor of BTK demonstrating clear activity and good tolerability.
He discusses two reports on the TRANSCEND anti-CD19 CAR T-cell trial. The first report compares CAR-T monotherapy to a combination of CAR-T therapy and ibrutinib. The second evaluates data from CAR-T monotherapy demonstrating a complete remission rate of 40%-60% along with undetectable MRD in bone marrow.
Finally, Dr Wierda reviews data from the UNITY phase 3 trial evaluating the combination of umbralisib plus ublituximab vs obinutuzumab plus chlorambucil in both the frontline and relapsed settings. The combination targeted therapy resulted in improved survival compared with the chemoimmunotherapy.
--
William G. Wierda, MD, PhD, Professor; Medical Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
William G. Wierda, MD, PhD, has disclosed the following relevant financial relationships:
Contracted research for: GlaxoSmithKline/Novartis; AbbVie; Genentech; Pharmacyclics LLC; Acerta Pharma, Inc.; Gilead Sciences; Juno Therapeutics; KITE Pharma; Sunesis; Miragen; Oncternal Therapeutics, Inc.; Cyclacel; Loxo Oncology, Inc.; Janssen; Xencor.
